Search

Introduction: Early childhood is a critical time when the benefits of early interventions are intensified, and the adverse effects of risk can be reduced. For the optimal provision of early intervention, professionals in the field are required to have specialised knowledge and skills in implementing these programmes. In the context of South Africa, there is evidence to suggest that therapists are ill-prepared to handle the unique challenges posed in neonatal intensive care units and wards with at-risk infants in the first few weeks of life. This is attributed to several reasons; however, irrespective of the causative factors, the need to bridge this knowledge-to-practice gap remains essential., Methods and Analysis: This study is a multimethod stakeholder-driven study using a scoping review followed by an appreciative inquiry and Delphi process that will aid in the development, implementation and evaluation of a knowledge translation intervention to bridge knowledge-gaps in occupational and physiotherapists working in the field. Therapists currently working in the public health sector will be recruited for participation in the various stages of the study. The analysis will occur via thematic analysis for qualitative data and percentages and frequencies for descriptive quantitative data. Issues around trustworthiness and rigour, and reliability and validity, will be ensured within each of the phases, by use of a content validity index and inter-rater reliability for the Delphi survey; thick descriptions, peer debriefing, member checking and an audit trail for the qualitative data., Ethics and Dissemination: The study has received full ethical approval from the Health Research and Knowledge Management Directorate of the Department of Health and a Biomedical Research Ethics Committee. The results will be published in peer-reviewed academic journals and disseminated to the relevant stakeholders within this study., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Purpose: The LHIV-Manitoba cohort was developed as a way to provide a comprehensive source of HIV-related health information in the central Canadian Prairie province of Manitoba. The cohort will provide important information as we aim to better understand local HIV epidemiology and address key knowledge and practice gaps in HIV prevention, treatment and care programming in the province., Participants: In total, 890 individuals, aged 18 or older and living or receiving HIV care in Manitoba are enrolled in the cohort. A complete clinical dataset exists for 725 participants, which includes variables on sociodemographic characteristics, comorbidities and co-infections, self-reported HIV exposure categories and HIV clinical indicators. A limited clinical dataset exists for an additional 165 individuals who were enrolled posthumously. 97.5% of cohort participants' clinical records are linked to provincial administrative health datasets., Findings to Date: The average age of cohort participants is 49.7 years. Approximately three-quarters of participants are male, 42% self-identified as white and 42% as Indigenous. The majority of participants (64%) reported condomless vaginal sex as a risk exposure for HIV. Nearly one-fifth (18%) of participants have an active hepatitis C virus infection and the cohort's median CD4 count increased from 316 cells/mm 3 to 518 cells/mm 3 between time of entry into care and end of the first quarter in 2019., Future Plans: The LHIV-Manitoba cohort is an open cohort, and as such, participant enrolment, data collection and analyses will be continually ongoing. Future analyses will focus on the impact of provincial drug plans on clinical outcomes, determinants of mortality among cohort participants and deriving estimates for a local HIV care cascade., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Introduction: Ulcerative colitis (UC) is a chronic inflammatory disease that mainly affects the colon in young patients. Typical symptoms of UC are bloody diarrhoea and faecal urgency, which disturb the quality of life (QOL) of patients, and intractable UC leads to hospitalisation and colectomy. To improve relevant outcomes such as symptoms, QOL and colectomy, many clinical questions need to be resolved regarding what the ideal lifestyle, psychosocial burden and optimal practice patterns are. In this YOu and Ulcerative colitis: Registry and Social network (YOURS) study, we will investigate the effect of lifestyle, psychosocial factors and practice patterns on patient-reported outcomes (PRO), hospitalisation rate and colectomy rate in Japanese patients with UC., Methods and Analysis: For this prospective cohort study, we recruited 2006 patients from five hospitals (Tokyo and Chiba; May 2018-January 2019). Patients will be able to access their own data and compare them with summarised data from all patients on the website beyond the YOURS study. At baseline, patients will answer a questionnaire regarding lifestyle (diet, exercise, sleep and work), psychosocial factors (stress, depression and social support) and PRO (symptoms and QOL). Information on practice patterns (eg, medications, endoscopy frequency) will be collected from electronic medical records. Gaps between patients' needs and healthcare professionals' practice will be identified. Follow-up surveys will be conducted periodically for approximately 3 years. Research questions suggested by patients and healthcare professionals may be used in subsequent surveys. Results from the YOURS study will demonstrate optimal UC management strategies to improve relevant outcomes.The study was approved by the ethics committees of five investigational sites before starting the study. The results will be submitted to journals.UMIN000031995., Competing Interests: Competing interests: KM has received grants and personal fees from Sekisui Medical, AbbVie and Thermofisher Scientific, grants from Alfresa Pharma Corporation, personal fees from Mitsubishi-Tanabe Pharma, Eisai, Kyorin Pharmaceutical, Asahi Kasei Medical, Mochida Pharmaceutical, Kissei, Kyowa Hakko Kirin, Takeda Pharmaceutical, Covidien, Janssen Pharmaceutical, Pfizer, EA Pharma, Astellas, Zeria Pharmaceutical, Celltrion and JIMRO. JF is an employee of Takeda Pharmaceutical Company Limited and owns restricted stocks of Takeda Pharmaceutical Company Limited and GlaxoSmithKline. TH has received grants and personal fees from AbbVie GK, JIMRO Co., EA Pharma and Zeria Pharmaceutical, grants from Otsuka Pharmaceutical Co., personal fees from Mitsubishi-Tanabe Pharm, Kyorin Pharmaceutical, Janssen, Mochida Pharmaceutical, Takeda Pharmaceutical, Gilead Sciences, Celltrion, Nippon Kayaku, Kissei Pharmaceutical, Miyarisan Pharmaceutical, Ferring Pharmaceutical, Eli Lilly, Pfizer Japan and Nichi-Iko Pharmaceutical. MW has received grants and personal fees from Ajinomoto Pharma Co., Kyorin Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Takeda Pharmaceutical Co., Eisai Co., Otsuka Pharma Co., Kyowa Hakko Kirin Co., Zeria Pharmaceutical Co., JIMRO Co., Asahi Kasei Kuraray Medical Co., EA Pharma Co., AbbVie GK, Astellas Pharma, Daiichi Sankyo Co., Chugai Pharmaceutical Co., Gilead Sciences, Nippon Kayaku Co., Mochida Pharmaceutical Co., Janssen Pharmaceutical K.K., Celltrion Healthcare Co., Pfizer Japan and Miyarisan Pharmaceutical Co.; grants from Toray Industries, MSD K.K., Bristol-Myers K.K., Taiho Pharmaceutical Co., Ayumi Pharmaceutical Co. and Shionogi & Co. and personal fees from Kissei Pharmaceutical Co., Nichi-Iko Pharmaceutical Co., Celgene and Novartis. TH has received grants and personal fees from Mitsubishi Tanabe Pharma, EA Pharma, AbbVie GK, JIMRO, Zeria, Kyorin Pharmaceutical, Takeda Pharmaceutical, Pfizer Japan and Mochida Pharmaceutical; grants from Asahi Kasei Kuraray Medical, Daiichi-Sankyo, Nippon Kayaku and Astellas; and personal fees from Celgene, Janssen Pharmaceutical and Nichi-Iko Pharmaceutical. SF has received lecture fees from Takeda Pharmaceutical Co., Chugai Pharmaceutical Co., Kyowa Hakko Kirin Co., Daiichi Sankyo Co., Bayer Yakuhin, Otsuka Pharmaceutical Co., Pfizer Japan and MSD K.K., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)